By Matt Smith, CNN <\/p>\n
updated 7:06 PM EST, Thu February 27, 2014 <\/p>\n
STORY HIGHLIGHTS <\/p>\n
(CNN) -- A promising way to stop a deadly disease, or an uncomfortable step toward what one leading ethicist called eugenics? <\/p>\n
U.S. health officials are weighing whether to approve trials of a pioneering in vitro fertilization technique using DNA from three people in an attempt to prevent illnesses like muscular dystrophy and respiratory problems. The proposed treatment would allow a woman to have a baby without passing on diseases of the mitochondria, the \"powerhouses\" that drive cells. <\/p>\n
The procedure is \"not without its risks, but it's treating a disease,\" medical ethicist Art Caplan told CNN's \"New Day\" on Wednesday. Preventing a disease that can be passed down for generations would be ethical \"as long as it proves to be safe,\" he said. <\/p>\n
\"These little embryos, these are people born with a disease, they can't make power. You're giving them a new battery. That's a therapy. I think that's a humane ethical thing to do,\" said Caplan, the director of medical ethics at New York University's Langone Medical Center. <\/p>\n
\"Where we get into the sticky part is, what if you get past transplanting batteries and start to say, 'While we're at it, why don't we make you taller, stronger, faster or smarter?' \" <\/p>\n
But Susan Solomon, the director of the New York Stem Cell Foundation, said there are no changes to existing genes involved. <\/p>\n
\"There is no genetic engineering. It isn't a slippery slope. It's a way to allow these families to have healthy children,\" said Solomon, whose organization developed the technique along with Columbia University researchers. <\/p>\n
<\/p>\n
Follow this link:<\/p>\n
FDA considers 3-parent embryos<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" By Matt Smith, CNN updated 7:06 PM EST, Thu February 27, 2014 STORY HIGHLIGHTS (CNN) -- A promising way to stop a deadly disease, or an uncomfortable step toward what one leading ethicist called eugenics? Continue reading